Schroders Capital's venture capital investment focus is on selective early-stage opportunities, aiming to capture distributed innovation across diverse global regions and ecosystems. Their strategy involves backing top-tier managers, diversifying across managers, geographies, and sectors, and emphasizing operational value-add.
Portfolio
6
Fund Size
—
Top Stage
Series B
Last 12 Mo
3
Team
NR
Nils Rode
Chief Investment Officer, Private Markets
PF
Paul Forshaw
Chief Executive Officer, Future Growth Capital
GW
Georg Wunderlin
Chief Executive Officer
MP
Minal Patel
Global Head of Infrastructure
RE
Rainer Ender
Global Head of Private Equity
Stage Distribution
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Kainova Therapeutics | Series B | $32M | Feb 2026 |
| AAVantgarde Bio | Series B | $141M | Nov 2025 |
| Cyberhaven | Series D | $100M | Apr 2025 |
| Cera | Growth | $150M | Jan 2025 |
| iOnctura | Series B | $80M | Jun 2024 |
| Graphcore | Series E | $222M | Dec 2020 |
Top Co-Investors
Panacea Venture1 shared
Stepstone1 shared
Industry Ventures1 shared
Ontario Teachers' Pension Plan1 shared
Fidelity Investments1 shared
Baillie Gifford1 shared
Draper Esprit1 shared
Atlas Venture1 shared
Forbion1 shared
ATHOS1 shared
CDP Venture Capital1 shared
NEVA SGR1 shared
Sixty Degree Capital1 shared
Willett Advisors1 shared
M Ventures1 shared
INKEF Capital1 shared
Vi Partners1 shared
3B Future Health Fund1 shared
Last updated: 1 March 2026